---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006717"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:57:45.065703+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCryst pipeline update: five programs to enter clinic by 2025, R&D spend guided $230-240M in 2024

## Summary
- BCX17725 (fusion protein KLK5 inhibitor) for Netherton syndrome entering clinic 2H 2024.
- Avoralstat + Clearside SCS Microinjector for DME to enter clinic in 2025.
- Oral C5 inhibitor for generalized myasthenia gravis to enter clinic in 2025.
- Bifunctional complement inhibitor targeting multiple pathways for IgAN and lupus nephritis to enter clinic in 2025.
- 2024 R&D spending guided at $230-240M, up from projected 2023 spending of $25-35M.

## SEC filing metadata
- accession: 0001171843-23-006717
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323006717/0001171843-23-006717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323006717/f8k_110323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006717
- JSON: https://secwatch.observer/filing/0001171843-23-006717.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.